This alliance will serve to bring Inflamax’s expertise in Environmental Exposure Chambers (EEC) together with that of the VCC’s, to provide the highest level of allergen challenge services worldwide.

Toronto, ON (PRWEB) June 16, 2016

Inflamax Research Inc., a full service contract research organization (CRO) specializing in allergy, asthma, and ocular research utilizing environmental exposure chamber technology, with facilities in North America, announced today that is has entered into a strategic alliance with the Vienna Challenge Chamber or VCC, located in Austria. This strategic alliance will allow the expansion of multicenter EEC studies across the globe. Inflamax announced in 2015 an alliance in Japan with InCROM to bring their mobile EEC, mEEC™ system, to Japan. The mEEC™ is a state of the art facility designed to expose patients to controlled levels of airborne allergen, similar to those experienced in their daily lives, while reducing the variability of results, and increasing patient compliance compared to typical field trials.

“Our strategic alliance with the VCC team will further our goal to be able to effect multicenter EEC studies worldwide. We are excited to work with the renowned scientists, Drs. Petra and Réné Zieglmayer who have been thought leaders and pioneers in the development of the VCC system,” says Dr. Piyush Patel, CEO & Principle Scientist of Inflamax Research.

“We are pleased to be working together with Inflamax Research. We want to streamline our scientific efforts to develop the EEC standards and help our collaboration partners realize the full potential of their drug research. In our scientific approach we are aligned and excited to announce this alliance,” said Dr. Petra Zieglmayer.

advertisement | advertise on newsday

About Inflamax Research
Inflamax Research Inc. is a full-service, Clinical Research Organization (CRO) with clinical research facilities in both Canada (Mississauga) and the USA (New Jersey). They specialize in allergy and asthma clinical research with over 25 years’ experience in the conduct of clinical trials and are a leader in Environmental Exposure Chamber technology. Inflamax is experienced in phase I clinical pharmacology through to late phase, global, and multi-centre clinical research services, as well as post marketing studies.

About Vienna Challenge Chamber - VCC
The Vienna Challenge Chamber is a scientific institution conducting basic and clinical research on inhalative allergies like rhinoconjunctivitis and asthma. The VCC research group is a pioneer in allergen exposure chamber technology: the first system worldwide was built in 1987 at the Medical University, currently the third generation of the system is in operation. Research activities are focussing on clinical as well as immunological monitoring of type 1 allergic reactions also in connection with phase 2 and 3 clinical evaluation of new compounds. Several hundred publications in peer reviewed journals document these research activities impressively.

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/06/prweb13493043.htm